Recombinant 2019-nCoV 2019-nCoV Papain-Like Protease

Cat.No.: CR77

Description
Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed.
Accession #:QHD43415.1
Known as:Papain-like Protease; PLpro; PL-PRO; pp1a; Replicase polyprotein 1a
Formulation
Supplied as a 0.2 μm filtered solution of 20mM Tris-Hcl, 10 mM mercaptoethanol [BME], 20%glycerol, pH 7.5.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
Storage
Store at < -20°C, stable for 6 months after receipt.
Please minimize freeze-thaw cycles.
Background
Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.

Send Message